Lycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for ...
Rapport's phase 2 bipolar win strikes chord with analysts despite falling short of original ambition
Rapport Therapeutics’ phase 2 bipolar mania study has hit its primary endpoint, furthering the biotech’s efforts to make RAP-219 a multi-indication blockbuster. However, the effect size fell short of ...
Medtech M&A reached its highest level in more than a decade, EY found, with a total disclosed deal value of roughly $130 ...
Nano24’s inhaled exosome therapy reduced respiratory failure in patients with acute respiratory distress syndrome (ARDS), ...
Amid the Chinese biopharma licensing boom, Hengrui Pharmaceuticals stands out from the crowd. | Amid the Chinese biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results